Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease.
Saved in:
| Title: | Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease. |
|---|---|
| Authors: | Colwill M; Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK.; Institute of Infection and Immunity, City St George's, University of London, London, UK., Honap S; Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK.; School of Immunology and Microbial Sciences, King's College London, London, UK., Danese S; Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Peyrin-Biroulet L; Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, Nancy, Vandœuvre-lès-Nancy, France. |
| Source: | Clinical and experimental gastroenterology [Clin Exp Gastroenterol] 2025 Sep 30; Vol. 18, pp. 233-249. Date of Electronic Publication: 2025 Sep 30 (Print Publication: 2025). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101532800 Publication Model: eCollection Cited Medium: Print ISSN: 1178-7023 (Print) Linking ISSN: 11787023 NLM ISO Abbreviation: Clin Exp Gastroenterol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
